Advanced search
Publication Cover
Future Oncology Volume 5, 2009 - Issue 9
Submit an article Journal homepage
1,085
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Targeting of AML-Leukemic Stem Cells with Monoclonal Antibodies

Erwin M Leea Children’s Cancer Institute Australia for Medical Research Randwick, AustraliaView further author information
&
Richard B Lockb NHMRC Senior Research Fellow, Associate Professor and Head Leukaemia Biology Program Children’s Cancer Institute Australia for Medical Research, PO Box 81, High Street, Randwick, NSW2031Australia. [email protected]Correspondence[email protected]
View further author information
Pages 1327-1330 | Published online: 10 Nov 2009

Bibliography

  • Estey E , DohnerH: Acute myeloid leukaemia.Lancet368(9550), 1894–1907 (2006).
  • Mayer RJ , DavisRB, SchifferCAet al.: Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.N. Engl. J. Med.331(14), 896–903 (1994).
  • Estey E : New drugs in acute myeloid leukemia.Semin. Oncol.35(4), 439–448 (2008).
  • Hope KJ , JinL, DickJE: Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity.Nat. Immunol.5(7), 738–743 (2004).
  • Taussig DC , Miraki-MoudF, Anjos-AfonsoFet al.: Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.Blood112(3), 568–575 (2008).
  • Ishikawa F , YoshidaS, SaitoYet al.: Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.Nat. Biotechnol.25(11), 1315–1321 (2007).
  • Guan Y , GerhardB, HoggeDE: Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML).Blood101(8), 3142–3149 (2003).
  • Pearce DJ , TaussigD, ZibaraKet al.: AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML.Blood107(3), 1166–1173 (2006).
  • van Rhenen A , FellerN, KelderAet al.: High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.Clin. Cancer Res.11(18), 6520–6527 (2005).
  • Guzman ML , NeeringSJ, UpchurchDet al.: Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells.Blood98(8), 2301–2307 (2001).
  • Heuser M , SlyLM, ArgiropoulosBet al.: Modelling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal.Blood DOI: 10.1182/blood-2009-06-227603 (2009) (Epub ahead of print).
  • Gal H , AmariglioN, TrakhtenbrotLet al.: Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells.Leukemia20(12), 2147–2154 (2006).
  • van Rhenen A , MoshaverB, KelderAet al.: Aberrant marker expression patterns on the CD34+CD38-stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.Leukemia21(8), 1700–1707 (2007).
  • Graf M , HechtK, ReifS, Pelka-FleischerR, PfisterK, SchmetzerH: Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.Eur. J. Haematol.72(2), 89–106 (2004).
  • Jin L , LeeEM, RamshawHSet al.: Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells.Cell Stem Cell5(1), 31–42 (2009).
  • Testa U , RiccioniR, MilitiSet al.: Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis.Blood100(8), 2980–2988 (2002).
  • Hauswirth AW , FlorianS, PrintzDet al.: Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.Eur. J. Clin. Invest.37(1), 73–82 (2007).
  • Vercauteren S , ZapfR, SutherlandH: Primitive AML progenitors from most CD34(+) patients lack CD33 expression but progenitors from many CD34(-) AML patients express CD33.Cytotherapy9(2), 194–204 (2007).
  • McKoy JM , AngelottaC, BennettCLet al.: Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.Leuk. Res.31(5), 599–604 (2007).
  • Majeti R , ChaoMP, AlizadehAAet al.: CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.Cell138(2), 286–299 (2009).
  • Piloto O , LevisM, HusoDet al.: Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.Cancer Res.65(4), 1514–1522 (2005).
  • Jin L , HopeKJ, ZhaiQ, Smadja-JoffeF, DickJE: Targeting of CD44 eradicates human acute myeloid leukemic stem cells.Nat. Med.12(10), 1167–1174 (2006).
  • Tavor S , PetitI, PorozovSet al.: CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.Cancer Res.64(8), 2817–2824 (2004).
  • van Rhenen A , van DongenGA, KelderAet al.: The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.Blood110(7), 2659–2666 (2007).
  • Korver W , ZhaoX, SinghSet al.: Monoclonal antibodies against IREM-1: potential for targeted therapy of AML.Leukemia23(9), 1587-97 (2009).
  • Foran JM , NortonAJ, MicallefINet al.: Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.Br. J. Haematol.114(4), 881–883 (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.